Introduction {#sec1}
============

Immunoglobulin G (IgG) replacement therapy is the mainstay of treatment in many primary immunodeficiency diseases (PIDD) associated with humoral immune defects, including common variable immunodeficiency disease (CVID), congenital hypogammaglobulinemia and agammaglobulinemia.[@bib1] While intravenous immunoglobulin (IVIG) was the most common mode of replacement in 1980--1990, subcutaneous IgG (SCIG) administration has become increasingly common in clinical practice since the 1990s.[@bib2] Both IVIG and SCIG have been regarded therapeutically equivalent (have same efficacy for prevention of bacterial infections) in patients with PIDD[@bib3]^,^[@bib4] and choice of the use of IVIG vs. SCIG has to take into account the comparative advantages and disadvantages between these for a given patient. For example, advantages of SCIG being fewer systemic adverse events,[@bib4]^,^[@bib5] improved quality of life[@bib5]^,^[@bib6] and stable IgG levels[@bib6]^,^[@bib7] and disadvantages being more local infusion sites reactions accounting for adverse events[@bib8], [@bib9], [@bib10], [@bib11] and requirement of frequent infusions (weekly vs. monthly).[@bib4]^,^[@bib5]

It is unclear if there are universally accepted threshold IgG levels that correlate with adequate protection from severe infections. Serum IgG concentrations ≥500 mg/dl following IgG therapy have been recommended for adequate protection from serious infections in PIDDs.[@bib12], [@bib13], [@bib14] The serum IgG trough level, defined as concentration preceding the next dose of immunoglobulin (Ig) infusion, has been regarded as an important guide to therapy.[@bib15] Several recent studies have shown higher serum IgG concentrations, resulting from higher intravenous IgG and subcutaneous IgG dosing regimens, associated with infection prevention and decreasing infection-associated morbidity.[@bib13]^,^[@bib16]^,^[@bib17] Data from earlier studies have endorsed IgG trough level of 500 mg/dl as an appropriate initial minimum target for infection prevention in PIDD.[@bib14]^,^[@bib18] However, subsequent clinical evidence has prompted recommendations for higher target levels of \>800 mg/dl[@bib19] and 650--1000 mg/dl[@bib20] in recent clinical guidelines. Due to inconsistent trough levels, a recommendation to individualize treatment plans based on symptoms and infections has been proposed.[@bib3] Studies have also suggested no significant differences in efficacy or adverse reaction rates between subcutaneous and intravenous immunoglobulin treatment.[@bib4]

In this systematic review and meta-analysis, we sought to compare IVIG vs. SCIG in PIDD patients and its effects on IgG trough levels, the overall incidence of infection and serious infections (including pneumonia) to help guide clinicians in appropriate clinical decision making.

Methods {#sec2}
=======

The preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement as recommended by the Cochrane Collaboration for reporting systematic reviews[@bib21] was used ([Fig. 1](#fig1){ref-type="fig"}). This systematic review included studies published from Jan 1, 2010, to May 30, 2018. A meta-analysis on studies earlier than 2010 was already carried out by Orange et al.;[@bib13] we focused our review on studies after 2010 to cover newer studies since the recent advancements in the treatment of these diseases. Searches of MEDLINE, EMBASE, Cochrane Library, and Scopus databases were carried out to identify eligible studies. A combination of subject headings (MeSH, EMTREE) and text words was used for each concept. Search terms and synonyms for \"immunologic deficiency\" and \"immunoglobulins\" were combined in the search with \"AND\" using Boolean logic. Synonyms for immune deficiency included \"immunologic deficiency syndromes\", \"common variable immunodeficiency\", \"dysgammaglobulinemia\", \"agammaglobulinemia\", \"hypogammaglobulinemia\" (the text words allowed for both American and British spellings). Synonyms for immunoglobulins included \"immunoglobulins\", "intravenous", "subcutaneous" abbreviations of IVIG, SQIG, as well as specific brand names such as Carimune, Gammagard, and subject headings which included specific routes of injection such as immunoglobulins/intravenous or immunoglobulins/subcutaneous were included.Fig. 1Flow chart describing systematic research and study selection processFig. 1

The eligibility criteria for this systematic review were (1) human subjects with a diagnosis of PIDD undergoing IgG treatment; (2) reported outcomes comparing IVIG, SCIG, or different dosage/forms of IVIG/SCIG; (3) Documented IgG trough level; (4) Studies showing an outcome of interest (overall infection, pneumonia/serious infection, or hospitalization rates). Studies without documented therapy studies not reporting any outcome of interest or definitions of those outcomes, and studies without a comparator were excluded from our analysis. Conference extracts were excluded. The language was restricted to English.

Study abstracts were screened by two investigators (PS and AJ), full-text articles were reviewed for those that fulfilled eligibility criteria and irrelevant articles were excluded. Disputes were settled with mutual agreement. To minimize data duplication as a result of multiple reporting, we compared articles from the same investigator. Relevant data were extracted by two investigators (PS and AJ) and checked by another (PK).

From each study, we extracted and tabulated details on the study source, design, patient with PIDD, type of PIDD included, mean age in years, percentage of female patients, percentage of CVID patients, the region of study, the total population of study and duration of the study ([Table 1](#tbl1){ref-type="table"}). Furthermore, we extracted the details on treatment, including the type of treatment IgG used, comparison group, dosing protocol, IgG trough level, pneumonia rate, overall infection rate, days of hospitalizations, days missed from school/work and adverse events per patient-year ([Table 2](#tbl2){ref-type="table"}).Table 1Baseline Characteristics of clinical studies included in systematic review and meta-analysis.Table 1SNStudiesStudy designRegionTotal Population of StudyStudy durationTreatment IgG used (Brand name)ComparisonNo. of patients (n)Mean age in years (SD/range)Female gender (n, %)1Aydiner 2015[@bib29]Prospective, observationalTurkey1610 monthsSCIG5--10% IVIG vs. SCIG167.5 (0--33 years)7 (43.7%)2Berger 2010[@bib30]Open-label, uncontrolled trialGermany51 (adults = 42, children = 9), (3--66 years)12 months16% SCIG (Vivaglobin)Historic IVIG vs.5137.8 ± 19.4030 (58.8%)16% SCIG3110.4 ± 20.2418 (58.1%)3Ballow 2016[@bib31]Phase IV, multi-center, open-label studyUSA24 (2--16 years)12 months5% DIF IVIG (Flebogamma)Historic IVIG vs. 5% DIF IVIG249.0 (2.0--16.0)5 (20.8%)4Bezrodnik 2013[@bib8]Observational, prospective/retrospective, open-label multicenter studyArgentina15 (6--18 years)36 weeks16% SCIG (Beriglobina P)16% SCIG1510.6 (3.7)4 (27%)5Bezrodnik 2014[@bib32]Observational, descriptive and ambispective studyArgentina32 (8 months - 40 years)36 weeks16% SCIG (Beriglobina P)Historic IVIG vs. SCIG (15 via pump and 2 via push)3211 (8--40)15 (46.9%)6Borte 2017[@bib9]Prospective, non-controlled clinical trialEurope49 (\>2 years)52 weeksIVIG 10% (Kiovig)/SCIG 16% (Subcuvia)IVIG 10%/SCIG 16% (period1) vs.33 (IVIG), 16 (SCIG16%)17 (2--67)19 (38.8%)SCIG 20%SCIG 20% (period2)49 (SCIG 20%)7Borte 2017[@bib10]Prospective, open-label, non-controlled, non-randomized, multicenter, phase 3 studyUSA and Europe51 (13 children, 12 adolescents, 26 adults)12 monthsIVIG 10% (Panzyga)3-weekly IVIG then IVIG 10%2126.2 ± 21.214 (66.7%)4-weekly IVIG then IVIG 10%3027.2 ± 18.219 (63.3%)8Borte 2011[@bib33]Prospective, open-label, multicenter, single-arm, phase IIIEurope18 (2--11 years) and 5 (12--15 years) and 28 (16--64 years)12 weeks (wash-in/wash-out period)+28 weeks efficacy periodSCIG 20% (Hizentra)IVIG vs. 20%SCIG517.2 ± 2.5 (children), 14 ± 1 (adolescents), 34.1 ± 12.7 (adults)5 (27.8%) children, 0 adolescents, 11 (39.3%) adults9Haddad 2012[@bib6]Comparative study for Open-label, multi-center, single-arm designUSA and EuropeEU = 4612 weeks wash-in/wash-out period + efficacy period (28 weeks in Europe and 52 weeks in USA)SCIG 20% (Hizentra)SCIG 20% same dose as historic IVIG4621.5 ± 15.615 (33%)USA = 38SCIG 20% 1.5 x dose as historic IVIG3836.3 ± 19.521 (55%)10Hagan 2010[@bib11]Prospective, open-label, multicenter, single-arm, phase IIIUSA49 (5--72 years)12 weeks wash-in/wash-out period and 12-month efficacy periodSCIG 20% (IgPro20)IVIG then SCIG 20%4936.3 ± 19.5221 (55.3%)11Jolles 2011[@bib34]Prospective, open-label, multicenter, single-arm, phase IIIEurope53 (17 \< 12 years, 5 \< 16 years,31 ≥ 16 years).12-week wash-in/wash-out period, 28 weeks efficacy periodSCIG 20% (Hizentra)Switch from IVIG to SCIG 20%46 (ITT), 23 (PPK)21.5 ± 15.615 (32.6%)12Kanegane 2014[@bib35]Prospective, multicenter, open-label, single-arm, phase IIIJapan25 (2--12 years = 11, 12--16 years = 8, 16--65 years = 26),12-week wash-in/wash-out period with 12-week efficacy periodIgPro20 SCIG (Hizentra)Switch from IVIG to SCIG 20%24 (ITT), 21 (PPK)17.5 (3--58) ITT, 19(3--58) PPK9 (37.5%) ITT, 7 (33.3%) PPK13Krivan 2016[@bib36]Open-label, prospective, multicenter, single-arm studyEurope62 (2--61 years), 36 adults and 26 pediatrics12 monthsIVIG (IqYmune)Switch from IVIG to IqYmune6227.4 (2--61)19 (30.6%)14Melamed 2016[@bib37]Open-label, multi-center, non-randomized phase 4 studyUSA(7), Chile(1), Israel (1)25 (3--16 years)12 months5% IVIG (Gammaplex)Switch from IVIG to IVIG 5%14 on 21-day infusion and 11 on 28-day infusion10.4 ± 3.846 (24%)15Moy 2010[@bib38]Prospective, open-label, multi-center, non- comparativeUSA50 (≥3 years)12 months5% IVIG with and 5 g d-sorbitol (Gammaplex 5%)Switch from IVIG to 5% IVIG22 on 21-day and 28 on 28-day infusion schedule44 ± 19.1024 (48%)16Patel 2015[@bib39]Retrospective chart reviewUSA88 (0-\<2 years = 34, 2--5 years = 54)45.5 monthsSCIG 20% (Hizentra)Historic Hizentra use8834 months (2-59)35 (40%)17Quinti 2011[@bib17]Prospective, multi-centerItaly302 (CVID + XLA)3.8 years (CVID)\
5.8 years (XLA)IVIGIVIG in CVID vs. XLA30228.7 ± 18.4 (3--68 years) (CVID)NA4.9 ± 6.2 (16 days-40.9 years) (XLA)18Stein 2016[@bib40]Prospective, open-label, single-arm, multicenter, historically controlled, phase IIIUSA and Canada40 (2--70 years)- 39 in US and 6 in Canada12 months10% IVIG (Kedrion)Historic Hizentra use (mean age of initiation of Hizentra 34 months)8834 months (2-59)35 (40%)19Suez 2016[@bib41]Prospective, open-label clinical trialUSA and Canada74 (≥2 years)52 weeksIVIG 10% and SCIG 20%7439.9 ± 20.713 (29%)20Viallard 2017[@bib42]Prospective, multicenter, non-randomized, open-labelFrance22 (18--70 years)9 months5% lyophilized IVIG (Tegeline) and IV Ig new generation (ClairYg IGNG)Period 1-IVIG 10% then SCIG 205 in period 2, 3 and 42236 (3--83)37 (48.1%)21Vultaggio 2015[@bib43]Prospective, observational, multicenterItaly50 (group A \>14 years = 43, Group B ≤ 14 years = 7)24 monthsSCIG 16% (Vivaglobin)IVIG/SCIG vs. SCIG 16%5041.9 ± 12.28 (36.4%)22Wasserman 2012[@bib44]Open-label, phase III, efficacy and pharmacokinetic studyUSA63 (6--11 years = 4, 12--17 years = 6, 18--64 years = 44, \>65 years = 9)12 monthsIVIG 10% (Biotest)IVIG vs. SCIG 16%5031.7 ± 15.719 (38%)23Wasserman 2012[@bib45]Prospective, multicenter, open label, phase IIIUSA and Canada87 (2--12 years = 14, ≥12 years = 73)14--18 monthsSCIG/IVIG preceded by rHyPH20 \[recombinant human hyaluronidase (IGHy)\]IVIG 10% infusion in 21 day vs. 28 day8741.2 ± 19.6832 (50.8%)24Wasserman 2016[@bib7]Prospective, open-label, non-controlled, multi-center studies, phase III trial \[Extension of earlier study (2012)\]USA and Canada63 (\<18 years = 15, ≥18 years = 48)30 monthsSCIG preceded by rHyPH20 \[recombinant human hyaluronidase (IGHy)\]SCIG/IVIG + rHyPH20 vs. IVIG/SCIG alone8735 (4--78)43 (49.4%)[^1]Table 2IgG dose, IgG trough level and outcomes of Primary Immunodeficiency disease patients in included clinical studies.Table 2SN.StudiesType of IgG usedDosing protocol, Mean(range) mg/Kg/weekIgG trough level (Mean ± SD) mg/dlSevere infections n (rate/patient/year)Overall infection (n, CI)-annual rate per patientDays of hospitalization (n, Mean ± SD)Days missed from work/school (n, Mean ± SD)Adverse events/patient/year1Aydiner 2015[@bib29]IVIG330--1250 mg/kg/wk976 ± 564 mg/dl07 events in 4 pts in 10 monthsnananaSCIG300--430 mg/kg/wk1025 ± 409 mg/dl2Berger 2010[@bib30]IVIG100--200 mg/kg/wk914.8 ± 273.37 mg/dl0.033.42na4.5/subject/year27.516% SCIG878 ± 234.77 mg/dl3Ballow 2016[@bib31]IVIG300--800 mg/kg/wk800--1000 mg/dl1 episode0.0510.2 ± 1.16.2 ± 17.720.25% IVIG4Bezrodnik 2013[@bib8]IVIG556 mg/kg/month (420--870)960.2 mg/dl3 episodes in IVIG/1 in SCIG1.40nana16% SCIG139 mg/kg/wk (105--181)1317 mg/dl (wk16), 1309.2 mg/dl (wk 24) and 1231.5 mg/dl (wk 36)0.40na0.145Bezrodnik 2014[@bib32]IVIG (48 weeks)na1005.33 ± 419.420 mg/dl4 episodes2--7nana0.1316% SCIG (9 months)133 mg/kg/wk (100--192)1205 ± 457.990 mg/dl3 episodes1--2nana0.026Borte 2017[@bib9]Period 1-IVIG 10% for 13 wk/SCIG 16% for 12 wks.125 ± 42 mg/kg/week (20% SCIG)IVIG 10% = 720 mg/dl SCIG 16% = 897 mg/dl0 IVIG, 1(0.27) SCIG 16%)6.29 rate (IVIG), 8.92 rate (SCIG 16%), 4.38 (SCIG 20%)1 (0.12) IVIG,2 (0.54) SCIG 16%90 (10.69) IVIG/187(50.42) SCIG0.058Period 2-SCIG 20% for 52 wkSCIG 20% = 827 mg/dl1(0.022)200(4.38)7(0.15)-SCIG710 (15.55)7Borte 2017[@bib10]10% IVIG (/3 weeks)485 mg/kg/month1100--1220 mg/dl3.68 (overall)\
4.19 (3 weekly))na37 absences (61.95%)Serious AE 13% (4 weekly) vs. 5% in 4 weekly10% IVIG (/4 weeks)810--870 mg/dl3.33 (4 weekly)1 (0.08)3.648Borte 2011[@bib33]IVIG/SCIG200--800 mg/kg/wk694 mg/dl (c), 790 mg/dl (a), 781 mg/dl (ad) g/l04.77/5.18 (a)/5.47 (ad)8.36(c),0(a),0.63(ad)1.7 (c), na (a), na (ad)0.04(c),0.035 (a),0.08(ad)/infusion20% SCIG129.9 mg/kg/wk -children(c),\
113.7 mg/kg/wk- adolescents (a) and 114.3 mg/kg/wk- adults (ad)786 mg/dl (c), 791 mg/dl (a), 831 mg/dl (ad)09Haddad 2012[@bib6]20% SCIG (1:1) EU120 mg/kg/wk810 ± 144 mg/dl05.183.4880.59 events/infusion (1:1)20% SCIG (1.5:1) USA210 mg/kg/wk1254 ± 322 mg/dl02.760.22.060.06 in 1:110Hagan 2010[@bib11]20% SCIG179.6--224.3 mg/kg (IgPro20)1210--1290 mg/dl02.760.22.06local AE = 0.592, other than local AE = 0.04311Jolles 2011[@bib34]IVIGPre study = 702 mg/dl1(wash out) = 0.03 events/patient/year5.183.4880.177/infusion20% SCIG120 ± 35.72 mg/kg/wk (20% SCIG)On infusion = 809 mg/dl12Kanegane 2014[@bib35]IVIG77.3 ± 30.5 mg/kg/month653 ± 140 mg/dl (IVIG)02.980.553.480.461/infusion20% SCIG87.8 ± 35.2 mg/kg/wk SCIG715 ± 151 mg/dl (SCIG)13Krivan 2016[@bib36]IqYmune220--970 mg/kg579 ± 203 mg/dl1 (0.017)3.790.891.010.45/infusion773/- 236 mg/dk (IVIG)14Melamed 2016[@bib37]IVIG 5% 21-day infusion300--800 mg/kg/wk21-day infusion = 987--1083 mg/dl2 (0.09)3.083.51.10.39/infusionIVIG 5% 28-day infusion28-day infusion = 822--882 mg/dl15Moy 2010[@bib38]IVIG 5%469.4 mg/kg/month (21-day infusion)\
466.2 mg/kg/month (28-day infusion)21-day infusion = 936--1240 mg/dl03.072 days8.731 AE/3 infusions28-day infusion = 833--1140 mg/dl16Patel 2015[@bib39]SCIG 20%674 mg/kg/wk (260--2000)\
552 mg/kg/month (IVIG)794 mg/dl (on IVIG) and 943 mg/dl (IGSC 20%)0.030.067 ratenana41 (47%) local AEs17Quinti 2011[@bib17]IVIGCVID- 398 ± 167 mg/kg/wkCVID-667 ± 176 mg/dl0.06--0.1 episodes patient-yearnanananaXLA-608 ± 273 mg/kg/wkXLA-758 ± 202 mg/dl0.03--0.11 episodes patient-year18Stein 2016[@bib40]10% IVIG501.7 mg/kg/month923.9 mg/dl2 (0.04)2.90.62.844(98%)- 450 events19Suez 2016[@bib41]IVIG 10% and SCIG 20%222 ± 71 mg/kg/wk1523 mg/dl with IGSC and 1200 mg/dl in IVIG 10% in 3 weeks03.86 in IVIG0.021.160.036/infusion2.41 in SCIG20Viallard 2017[@bib42]Tegeline442 mg/kg/month (286--608)Tegeline 805 ± 134 mg/dlTegeline-0Tegeline-4.35 (0--21.8)Tegeline-0Tegeline-8.8 (6.4--11.9)Tegeline-0.09ClairYgClairYg 917 ± 172 mg/dlClairYg-0ClairYg-4.3(0--15.1)ClairYg-0ClairYg-0.3(0.1--0.9)ClairYg-0.0821Vultaggio 2015[@bib43]IVIGMaintenance of total monthly dose of historic IVIG split into four weekly doses of SCIGBaseline 635 ± 242.8 mg/dl5 (0.056)33/39 patients (84.6%)- infection1.93 ± 4.08 (IVIG)15.27 ± 23.17 (IVIG)Local reactions (14/50 = 28%)SCIG 16%671 ± 217.5 mg/dl0.64 ± 2.94 (SCIG)2.26 ± 4.45 (SCIG)22Wasserman 2012[@bib44]IVIG 10%500 mg/kg/wk (254--1029)1076 ± 254 mg/dl (606--1780 mg/dl) in 21-days2 (0.035)2.6 (2.3--2.7)0.212.28937 events943 ± 215 mg/dl (487--2250) in 28-days23Wasserman 2012[@bib45]IVIG/SCIG + IGHy vs. IVIG/SCIG aloneIGHy at 75U/g IgG followed by IgG 10% at 155 mg/kg/wk\<12 yrs = 995 mg/dl, \>12 yrs 1070 mg/dl2(0.025)2.97 (IGHy)\
4.51 (IVIG)0.02 (IGHy) vs. 0.06 (IVIG)0.28 (IGHy) vs. 0.23 (IVIG)local AE = 0.199/infusion (IGHy)\
vs. 0.011/infusion (IVIG)\<12 yrs = 963 mg/dl, \>12 yrs = 1040 mg/dl24Wasserman 2016[@bib7]SCIG + IGHy vs. SCIG155 ± 53 mg/kg/week1135 mg/dl (2 week), 1195 mg/dl(3week), 983 mg/dl (4 week)5 (0.03)2.990.125.7510.68/subjects\' year[^2]

Study quality was formally evaluated by two investigators (PS and AD) using a modified Newcastle-Ottawa Quality Assessment Scale[@bib22] for observational studies. Any discrepancies were resolved by a third author (PK) (Supplementary File 1).

The outcomes from individual studies were calculated with RevMan, version 5.3 (Cochrane Collaboration, Oxford, United Kingdom). The Inverse-Variance method was used to compare the IVIG and SCIG trough levels. Risk Ratios (RRs) and 95% confidence intervals (CIs) were estimated using a random-effects method to control the heterogeneity as their assumption accounts for the presence of variability among the studies.[@bib23] The I[@bib2] statistic was used to estimate the percentage of heterogeneity among the studies. I[@bib2] values \< 30% were considered a low heterogeneity, 30%--60% as moderate, and \>60% as high.[@bib24] Peto odds ratio was used when the event rate was \<1%. DerSimonian and Laird random-effects method was used to pool the difference of IgG trough levels along with random-effect meta-regression to evaluate infection incidence per 100 mg/dl IgG trough increase through IVIG and SCIG. A p-value of \<0.05 was used as a level of significance. Publication bias was assessed by visual assessment of funnel plots (Supplementary File 2).

Results {#sec3}
=======

Our study included 24 studies that met our eligibility criteria, of which 21 were prospective, 2 were ambispective and 1 was a retrospective study ([Table 1](#tbl1){ref-type="table"}). Twelve studies were conducted in the United States, 10 in European countries (2 with the US), 4 in Canada (with the US), 2 in Argentina, 1 in Japan and Turkey each, and a multinational study by the US along with Chile and Israel. Treatment IgG products used and study durations were included. The mean patient age was 23.8 years in 24 studies, with 10 studies including those \<18 years and 14 including those \>18 years of age. Seven studies had more than 50% females, but males comprised the majority of the patient population overall. Disease types resulting in PIDD by the study are shown in [Supplemental Table 2](#appsec1){ref-type="sec"}. CVID was the predominant PIDD with 5 studies showing \>80% of CVID in the affected patient population, followed by XLA.

IVIG had been used in all the studies as a historical form of IgG administration and was compared with SCIG in 15 studies. IVIG administration frequency was every 3 or 4 weeks, whereas, SCIG dose was given weekly. Trough levels calculated in studies varied in terms of timing, with most of the levels drawn prior to the next IVIG and SCIG infusion. After reviewing the quality of studies, 11 studies were compared in the meta-analysis for trough levels as depicted in the forest plot ([Fig. 2](#fig2){ref-type="fig"}). Inclusion criteria of the studies stipulated documented diagnosis of PIDD requiring IgG therapy with a stable dose and trough level. However, in one study done by Borte et al., patients above 2 years of age with PIDD requiring 0.3--1 g/kg IgG for ≥ 3 months with serum IgG trough 5 g/l only were included. Patients with chronic infections with Hepatitis B, C or HIV, on antibiotics, abnormal liver and renal function tests, severe neutropenia, thrombotic episodes, malignancy, currently receiving immunosuppression, pregnant or nursing were excluded in most studies. Reported details on criteria for pneumonia diagnosis during the course of treatment with IVIG and SCIG therapy were limited, with some studies reporting the diagnosis based on history, chest X-ray, physical exam and need for hospitalization. Pneumonia was also sometimes reported as a \"serious infection\" separating it from the overall infections diagnosed during the treatment period. However, due to the low number of pneumonia diagnoses reported in the studies, regression analysis was focused on overall infections and serious infections. The annual rate of infection per patient was calculated, when not provided, for statistical analysis. Days of hospitalization, days missed from school and work, adverse events from the IVIG and SCIG therapy were reviewed and included if reported ([Table 2](#tbl2){ref-type="table"}).Fig. 2Trough levels in SCIG vs. IVIGFig. 2

Among the total 24 studies, 13 with IVIG therapy and 11 with SCIG therapy were reviewed owing to the availability of data required for comparative study and meta-analysis. Eleven studies which compared IVIG and SCIG therapy were included in the initial meta-analysis. Higher mean trough level attainment was evident in the SCIG group as compared to IVIG with a mean difference of 75.43 (CI 31.67--119.19), with moderate heterogeneity (I[@bib2] = 45%) ([Fig. 2](#fig2){ref-type="fig"}).

Among 6 studies comparing IVIG vs. SCIG in terms of the incidence of infection, the difference in risk of overall infections (Risk difference = 1.58, 95% CI: 0.75--3.33, p = 0.23, I^2^ = 96%) or serious infections was not statistically significant (Peto odds ratio = 1.94, 95% CI: 0.59--6.32, (p = 0.59, I = 0%), but a clinically relevant difference could not be ruled out ([Fig. 3](#fig3){ref-type="fig"}a and b).Fig. 3(a) and (b). Infection rates and serious infection rates in IVIG vs. SCIGFig. 3

Random-effects meta-regression analysis was used to analyze the increase in IgG trough level with a concomitant increase in IVIG and SCIG dose. No notable linear relationship with dose-dependent trough level was seen with either IVIG or SCIG therapy ([Fig. 4](#fig4){ref-type="fig"}a and b). However, across the studies included for regression analysis of IVIG and SCIG trough vs. infection incidence ([Fig. 5](#fig5){ref-type="fig"}a and b), each additional 100 mg/dl trough attained through SCIG was associated with a reduction in pneumonia incidence rate, as displayed in [Fig. 5](#fig5){ref-type="fig"}b. No significant trend was apparent within the IVIG trough range as depicted in [Fig. 5](#fig5){ref-type="fig"}a.Fig. 4(a) and (b). Effect of IVIG dose (mg/kg) on trough IgG level (mg/dl) and effect of SCIG dose (mg/kg) on trough IgG level (mg/dl). Each data point corresponds to a single observation period in a patient group of an included study. Abbreviations, C, 95% confidence interval; IVIG, intravenous immunoglobulin; SCIG, subcutaneous immunoglobulinFig. 4Fig. 5(a) and (b). Effect of IgG trough level (mg/dl) on infection incidence per patient-year in SCIG and IVIG groups. Each data point corresponds to a single observation period in a patient group of an included study. Abbreviations, C, 95% confidence interval; IVIG, intravenous immunoglobulin; SCIG, subcutaneous immunoglobulinFig. 5

Discussion {#sec4}
==========

Our study shows higher IgG trough levels in patients on SCIG vs. IVIG therapy. Among the 11 studies included in our meta-analysis of IVIG vs. SCIG trough level, consistently higher trough levels were observed with SCIG. A study done by Chapel et al. had also reported higher trough level in patients on SCIG therapy compared to IVIG, but doses differing as per infusion centers, differences in route of administration with no statistical evaluation of achieved serum IgG level make the comparison difficult.[@bib4] Similar findings were reported by Bonagura et al. as well.[@bib25] These findings may be due to the fact that pharmacokinetics of IgG tends to differ when smaller doses are given more frequently as compared to large boluses given on a monthly basis. SCIG therapy has been noted to have lower peaks and higher IgG troughs. A total IgG dose divided into three or four equal portions in weekly intervals is expected to have less variation and fluctuations of IgG trough level, approximately 900 mg/dl difference in peak and trough level after IVIG infusion in comparison to 100 mg/dl difference of the same after SCIG infusion.[@bib26] Another study by Radinski advocated that frequent SCIG dosing allows better maintenance of consistent serum IgG levels.[@bib27] Although our study favored higher level of IgG trough on SCIG therapy, increment in the level per dose increase did not have a linear correlation, and a similar finding was observed with IVIG therapy as well. This could have resulted from the variation of timing in measuring trough levels in different studies. Although the measurement of IgG trough level was done prior to infusion in most studies, some did not mention the exact timing of level drawn. Whether trough levels should be used as a guide for treatment remains controversial. Data from earlier studies have endorsed IgG trough level of 500 mg/dl as an appropriate initial minimum target for infection prevention in PIDD.[@bib18] However, subsequent clinical evidence has prompted recommendations for higher target levels of \>800 mg/dl[@bib19] and 650--1000 mg/dl[@bib20] in recent clinical guidelines. Due to inconsistent trough levels, preference for individualized treatment plan based on symptoms and infection prevention are considered.[@bib3] More studies are required to ascertain pharmacokinetic parameters such as maximal concentration in serum (C~max~), the time necessary to reach concentration after complete infusion (T~max~) and volume of distribution.

Similarly, a clear positive association of higher trough levels with lower infection rates was seen with SCIG in our meta-regression. Infection incidence rate with trough 800--900 mg/dl at 4.97 (CI 4.3--5.8) precipitously decreased to 1.85 (CI 0.14--3.6) and with trough level of 1200 + mg/dl which was statistically significant at p = 0.03. This relation, however, was not seen with IVIG therapy. Although we included 24 studies in our systematic review, we could only include 11 studies in our meta-analysis owing to lack of patient-level data. An earlier meta-analysis done by Orange et al. had also noted a significant reduction in pneumonia incidence (incidence rate ratio - 0.726, CI 0.658--0.801), with a 27% reduction in pneumonia incidence for each 100 mg/dl increment in trough IgG.[@bib13] While this study\'s analysis was limited to pneumonia incidence, authors did suggest the advantages of higher trough levels benefitting overall infection prevention as well. Comparison of overall or serious infections between IVIG vs. SCIG was not significantly different, however, a clinically significant difference cannot be ruled out due to a low number of patients and wide confidence interval seen.

The primary strength of this study is that it includes a large group of studies to quantify the relationship of infection rate and IgG trough levels in PIDD patients, along with the relationship of dose vs. trough level in IVIG as well as SCIG modes of treatment. Our results may have been confounded by a focused presentation on the efficacy of SCIG product, as most study trials were developed by pharmaceutical companies. Another caveat could be an effect seen by several studies in the past which noted serum IgG levels to rise continuously for months when previously untreated or under-treated patients received SCIG therapy.[@bib26]^,^[@bib28] Although the study includes studies done in several countries with large patient data, most studies are cohort studies, which limits the overall strength of evidence.

Our study did not show a significant difference in overall infections or serious infections with IVIG vs. SCIG, but a clinically significant difference cannot be ruled out. Based on our observation, weekly SCIG attained a higher trough level in comparison to monthly IVIG. Higher SCIG troughs were associated with lower infection rates, while IVIG troughs demonstrated no relationship. More randomized controlled trials are required to look at the effect of dosing with serum IgG trough levels, and more importantly its effect on infection prevention.
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[^1]: Legend: IgG- Immunoglobulin, n = number, SD- Standard Deviation, IVIG- Intravenous Immunoglobulin, SCIG- Subcutaneous Immunoglobulin, NA-not available, EU = Europe, USA= United States of America, ITT- Intent to treat, PPK- per-protocol pharmacokinetic, CVID= Common variable immunodeficiency disease, XLA = X-linked agammaglobulinemia

[^2]: Legend: IgG- Immunoglobulin, n = number, SD- Standard Deviation, wk-week, yrs-years IVIG- Intravenous Immunoglobulin, SCIG- Subcutaneous Immunoglobulin, na-not available, EU = Europe, USA= United States of America, ITT- Intent to treat, PPK- per-protocol pharmacokinetic, CVID= Common variable immunodeficiency disease, XLA = X-linked agammaglobulinemia, IGHy-recombinant human hyaluronidase
